Protein Phosphatase Inhibitor-1 Gene Therapy in a Swine Model of Nonischemic Heart Failure

Journal of the American College of Cardiology

Volumn 70, Issue 14, 2017, Pages 1744-1756

  Watanabe, Shin ^a   Ishikawa, Kiyotake ^a   Fish, Kenneth ^a   Oh, Jae Gyun ^a   Motloch, Lukas J ^a   Kohlbrenner, Erik ^a   Lee, Philyoung ^a   Xie, Chaoqin ^a   Lee, Ahyoung ^a   Liang, Lifan ^a   Kho, Changwon ^a   Leonardson, Lauren ^a   McIntyre, Maritza ^b   Wilson, Scott ^c   Samulski, R Jude ^d   Kranias, Evangelia G ^e   Weber, Thomas ^a   Akar, Fadi G ^a   Hajjar, Roger J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b ASKLEPIOS BIOPHARMACEUTICAL INC   (United States)

^c MPI RESEARCH   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

chimeric adenoassociated virus; contractility; inhibitor 1; intracoronary gene therapy; mitral regurgitation

Indexed keywords

BNP 116 I 1C; CARDIOVASCULAR AGENT; UNCLASSIFIED DRUG; VIRUS VECTOR; ENZYME INHIBITOR; PHOSPHOPROTEIN PHOSPHATASE 1; PROTEIN PHOSPHATASE INHIBITOR-1; SIGNAL PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARRHYTHMOGENESIS; ARTICLE; CARDIAC MUSCLE CELL; CELL ISOLATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GENE DELIVERY SYSTEM; GENE THERAPY; GENE TRANSFER; HEART ATRIUM CONTRACTION; HEART ATRIUM REMODELING; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE VOLUME; HEART VENTRICLE OVERLOAD; INTRACORONARY DRUG ADMINISTRATION; LOW DRUG DOSE; MALE; MITRAL VALVE REGURGITATION; NONHUMAN; PRECLINICAL STUDY; PRIORITY JOURNAL; RAT; YORKSHIRE PIG; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG MONITORING; GENE VECTOR; HEART FAILURE; METABOLISM; PATHOPHYSIOLOGY; PHARMACOLOGY; PIG; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; DRUG MONITORING; ENZYME INHIBITORS; GENETIC THERAPY; GENETIC VECTORS; HEART FAILURE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PROTEIN PHOSPHATASE 1; SWINE; TREATMENT OUTCOME;

EID: 85030765573     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2017.08.013     Document Type: Article

References (34)

1. Benjamin, E.J., Blaha, M.J., Chiuve, S.E., et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation 135 (2017), e146–e603.
2. Braunwald, E., The war against heart failure: the Lancet lecture. Lancet 385 (2015), 812–824.
3. Kawase, Y., Hajjar, R.J., The cardiac sarcoplasmic/endoplasmic reticulum calcium ATPase: a potent target for cardiovascular diseases. Nat Clin Pract Cardiovasc Med 5 (2008), 554–565.
4. Kranias, E.G., Hajjar, R.J., Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome. Circ Res 110 (2012), 1646–1660.
5. Hajjar, R.J., Potential of gene therapy as a treatment for heart failure. J Clin Invest 123 (2013), 53–61.
6. Nicolaou, P., Hajjar, R.J., Kranias, E.G., Role of protein phosphatase-1 inhibitor-1 in cardiac physiology and pathophysiology. J Mol Cell Cardiol 47 (2009), 365–371.
7. Neumann, J., Eschenhagen, T., Jones, L.R., et al. Increased expression of cardiac phosphatases in patients with end-stage heart failure. J Mol Cell Cardiol 29 (1997), 265–272.
8. El-Armouche, A., Rau, T., Zolk, O., et al. Evidence for protein phosphatase inhibitor-1 playing an amplifier role in beta-adrenergic signaling in cardiac myocytes. FASEB J 17 (2003), 437–439.
9. Chen, G., Zhou, X., Florea, S., et al. Expression of active protein phosphatase 1 inhibitor-1 attenuates chronic beta-agonist-induced cardiac apoptosis. Basic Res Cardiol 105 (2010), 573–581.
10. Pathak, A., del Monte, F., Zhao, W., et al. Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1. Circ Res 96 (2005), 756–766.
11. Nicolaou, P., Rodriguez, P., Ren, X., et al. Inducible expression of active protein phosphatase-1 inhibitor-1 enhances basal cardiac function and protects against ischemia/reperfusion injury. Circ Res 104 (2009), 1012–1020.
12. Fish, K.M., Ladage, D., Kawase, Y., et al. AAV9.I-1c delivered via direct coronary infusion in a porcine model of heart failure improves contractility and mitigates adverse remodeling. Circ Heart Fail 6 (2013), 310–317.
13. Ishikawa, K., Fish, K.M., Tilemann, L., et al. Cardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failure. Mol Ther 22 (2014), 1–8.
14. Mosterd, A., Hoes, A.W., Clinical epidemiology of heart failure. Heart 93 (2007), 1137–1146.
15. Sen, L., Cui, G., Fonarow, G.C., Laks, H., Differences in mechanisms of SR dysfunction in ischemic vs. idiopathic dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 279 (2000), H709–H718.
16. Brillantes, A.M., Allen, P., Takahashi, T., Izumo, S., Marks, A.R., Differences in cardiac calcium release channel (ryanodine receptor) expression in myocardium from patients with end-stage heart failure caused by ischemic versus dilated cardiomyopathy. Circ Res 71 (1992), 18–26.
17. Kawase, Y., Ly, H.Q., Prunier, F., et al. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol 51 (2008), 1112–1119.
18. Watanabe, S., Leonardson, L., Hajjar, R.J., Ishikawa, K., Cardiac gene delivery in large animal models: antegrade techniques. Methods Mol Biol (Clifton, NJ) 1521 (2017), 227–235.
19. Calcedo, R., Wilson, J.M., Humoral immune response to AAV. Front Immunol, 4, 2013, 341.
20. Zoghbi, W.A., Enriquez-Sarano, M., Foster, E., et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 16 (2003), 777–802.
21. Qian, J., Vafiadaki, E., Florea, S.M., et al. Small heat shock protein 20 interacts with protein phosphatase-1 and enhances sarcoplasmic reticulum calcium cycling. Circ Res 108 (2011), 1429–1438.
22. Xie, C., Hu, J., Motloch, L.J., Karam, B.S., Akar, F.G., The classically cardioprotective agent diazoxide elicits arrhythmias in type 2 diabetes mellitus. J Am Coll Cardiol 66 (2015), 1144–1156.
23. Nathwani, A.C., Tuddenham, E.G.D., Rangarajan, S., et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365 (2011), 2357–2365.
24. Jessup, M., Greenberg, B., Mancini, D., et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 124 (2011), 304–313.
25. Hoit, B.D., Left atrial size and function: role in prognosis. J Am Coll Cardiol 63 (2014), 493–505.
26. Welles, C.C., Ku, I.A., Kwan, D.M., Whooley, M.A., Schiller, N.B., Turakhia, M.P., Left atrial function predicts heart failure hospitalization in subjects with preserved ejection fraction and coronary heart disease: longitudinal data from the Heart and Soul Study. J Am Coll Cardiol 59 (2012), 673–680.
27. Greenberg, B., Butler, J., Felker, G.M., et al. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet 387 (2016), 1178–1186.
28. Hajjar, R.J., Ishikawa, K., Introducing genes to the heart: all about delivery. Circ Res 120 (2017), 33–35.
29. Asokan, A., Conway, J.C., Phillips, J.L., et al. Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nat Biotechnol 28 (2010), 79–82.
30. Ishikawa, K., Aguero, J., Naim, C., Fish, K., Hajjar, R.J., Percutaneous approaches for efficient cardiac gene delivery. J Cardiovasc Transl Res 6 (2013), 649–659.
31. Ghani, A., Delnoy, P., Adiyaman, A., et al. Predictors and long-term outcome of super-responders to cardiac resynchronization therapy. Clin Cardiol 40 (2017), 292–299.
32. Kao, D.P., Lowes, B.D., Gilbert, E.M., et al. Therapeutic molecular phenotype of beta-blocker-associated reverse-remodeling in nonischemic dilated cardiomyopathy. Circ Cardiovasc Genet 8 (2015), 270–283.
33. Otto, C.M., Clinical practice. Evaluation and management of chronic mitral regurgitation. N Engl J Med 345 (2001), 740–746.
34. Enriquez-Sarano, M., Akins, C.W., Vahanian, A., Mitral regurgitation. Lancet 373 (2009), 1382–1394.